Business Context and Reporting Period
This Form 8-K Current Report was filed by Supernus Pharmaceuticals, Inc. on December 23, 2013. The filing reports two material events: the resignation of a director and the receipt of FDA approval for a new drug formulation.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance and regulatory milestones rather than financial performance data.
Material Changes and Events
- Director Resignation: Michael Bigham resigned from the Board of Directors effective immediately on December 23, 2013. Mr. Bigham was the designee of Abingworth Bioventures IV LP. His departure aligns with Abingworth's practice of limiting board tenure after a company goes public.
- Committee Replacements: John M. Siebert, Ph.D., will replace Mr. Bigham on the Compensation Committee. M. James Barrett, Ph.D., will replace him on the Governance and Nominating Committee.
- FDA Approval: The U.S. Food and Drug Administration approved Orenitram (treprostinil) Extended Release Tablets for the treatment of pulmonary arterial hypertension in WHO Group I patients to improve exercise capacity.
- Technology and Partnership: The approved product utilizes Supernus's EnSoTrol osmotic technology platform and was developed under a Development and License Agreement with United Therapeutics Corporation.
Guidance, Outlook, and Risks
The filing does not contain forward-looking financial guidance, management commentary on future performance, or specific risk factors beyond the standard regulatory context of the FDA approval. The company is currently searching for a replacement director to fill the remainder of the term expiring at the 2014 annual meeting.
Investor Verification Checklist
- Verify the commercial launch timeline and expected revenue impact of the newly approved Orenitram Extended Release Tablets.
- Review the terms of the Development and License Agreement with United Therapeutics Corporation regarding royalties or milestones for Orenitram.
- Monitor the search for a new board director to replace Michael Bigham and assess the composition of the Compensation and Governance committees.
- Confirm the specific indications and patient population (WHO Group I) for which Orenitram is approved to understand market size.